Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€0.49

€0.49

-1.870%
-0.0092
-1.870%
€6.02
 
23.02.24 / Tradegate WKN: A12BHU / Symbol: AFMD / Name: Affimed / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction

Affimed N.V. Stock

A loss of -1.870% shows a downward development for Affimed N.V..
Based on 6 Buy predictions and 7 Sell predictions the sentiment towards Affimed N.V. is rather balanced.
On the other hand, the target price of 6 € is above the current price of 0.49 € for Affimed N.V., so the potential is actually 1121.0%.
So far the community has only identified positive things for Affimed N.V. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".

Pros and Cons of Affimed N.V. in the next few years

Pros
?
C******** o* t** e**********
?
M***** P*******
?
B****
Cons
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Affimed N.V. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Affimed N.V. -1.870% -9.918% -7.891% -44.070% 0.655% -88.683% -
Formycon AG -5.580% -7.985% 2.632% -37.562% -9.140% -18.226% 80.107%
MagForce AG -25.000% -11.765% -46.429% -50.000% 275.000% -99.932% -99.946%
Biofrontera AG -5.910% -2.957% -14.858% -72.857% -11.302% -88.241% -93.507%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-06-01

Upon an initial overview of the financials of Affimed, a company within the Biotechnology & Medical Research industry marked with US symbol AFMD, one may observe an interesting financial landscape. Although the company has experienced considerable net losses over the past three years, it maintains a substantial amount of cash on hand and continues to invest in research and development. Despite these investments, the company has yet to generate profits. A deep analysis of the company's financials may offer more insight.

In conclusion, Affimed's financial landscape displays both positives and negatives. The company benefits from a strong cash position, growing revenue, and substantial investments in research and development. However, it grapples with recurring net losses, high operating expenses, and negative free cash flow. Potential investors should consider these factors in their analysis and further investigate Affimed's prospects within the competitive Biotechnology & Medical Research industry.

Comments

Affimed (NASDAQ: AFMD) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for AFMD provided by MarketBeat
Show more

Affimed (NASDAQ: AFMD) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for AFMD provided by MarketBeat
Show more

Affimed (NASDAQ: AFMD) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for AFMD provided by MarketBeat
Show more